Cell therapy weekly: mRNA-engineered iPSC-derived NK cells developed for difficult-to-treat tumors

This week: several important steps have been announced in the preclinical development of Exacis Biotherapeutics’ ExaNK™ engineered NK cell therapy candidates, positive early data has been reported for a gene-edited cell therapy in sickle cell disease, the New York Stem Cell Foundation are developing a stem cell therapy to treat patients with age-related macular degeneration, and Organicell has entered into an agreement with the Centers for Disease Control and Prevention to determine the effectiveness of Zofin™ in experimental models of influenza infection. The news highlights: mRNA-engineered iPSC-derived NK cells developed for difficult-to-treat tumors Positive early data reported for gene-edited cell...